Le Lézard
Classified in: Health

Record Sales for Advion's Single Quadrupole Compact Mass Spectrometer


ITHACA, N.Y., Jan. 18, 2018 /PRNewswire/ -- Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced that, during the year ending December 31, 2017, it had reached several major milestones:

Advion, Inc. Logo

Commenting on the landmarks, Advion's CEO David B. Patteson stated, "Having launched the expression CMS product line about four years ago, we are exceedingly happy with the market adoption and product adaptation.  In 2012-2013, we quickly realized 10 units per quarter, and in 2017 approached 60/quarter. We recently launched our own (U)HPLC system, with full integration into our streamlined Mass Express software, and artfully combined with our popular TLC-CMS and ASAP sample introduction systems.  This allows a chemist to select, via software, which modality they desire, touch a screen icon and the setups and changeovers between operations are automatic."

Based upon publicly disclosed unit volumes from competitors, it is believed Advion enjoys >90% market share in the synthetic organic, natural product and peptide discovery chemistry deployed lab mass spec market. 

About Advion, Inc.
Advion develops, manufactures and globally supports mass spectrometers, chip-based ion sources, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees' commitment to create quality, flexible and fit-for-purpose solutions. More about Advion, Inc. can be found on our website, www.advion.com.

 

SOURCE Advion, Inc.


These press releases may also interest you

at 09:50
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...



News published on and distributed by: